This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the interim data from Phase 2 trial of Belzupacap sarotalocan (AURA-1101) in choroidal melanoma

Ticker(s): AURA

Who's the expert?

Institution: Southern California Permanente Medical Group

  • Ocular Oncologist and Vitreoretinal Surgeon
  • Assistant Clinical Professor of Ophthalmology at UCSF
  • Manages 300 patients yearly with choroidal melanoma
  • Very familiar with the published data on AU-1101

Interview Goal
Discuss Aura 1101 in choroidal melanoma

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.